Novartis releases Phase 3 trial data that assesses hyperlipidemia drug
Category: #health  By Mateen Dalal  Date: 2020-03-30
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Novartis releases Phase 3 trial data that assesses hyperlipidemia drug

Novartis, a renowned biopharmaceutical company, has reportedly released the outcomes of a prespecified analysis of pooled information from three Phase 3 trials that evaluate the efficacy and safety of inclisiran, the company’s first-in-class investigational therapy to treat hyperlipidemia in adults.

The new data was unveiled during a Late Breaker session during the American College of Cardiology’s Annual Scientific Session Together With the World Congress of Cardiology. The prespecified analysis of pooled information is consistent with safety and efficacy findings of the Phase 3 trial outcomes that were published in The New England Journal of Medicine.

The findings from Phase 3 studies further support the research presently underway for the Phase 3 ORION-4 study. The ORION-4 study aims to enroll 15,000 participants through 150 sites across the United Kingdom and the United States. The trial is looking for participants with pre-existing ASCVD (atherosclerotic cardiovascular disease) and who are not able reach their LDL-C goal.

Principal investigator of ORION-10, Professor of Medicine and Consultant in Cardiology at Mayo Clinic located in Rochester, Minnesota, R. Scott Wright, M.D. stated that there is still a compelling demand for a novel LDL-C-lowering treatment due to the residual risk faced by several patients with atherosclerotic cardiovascular disease and the oral lipid-lowering treatment not being able to gain crucial LDL targets on its own.

Wright further added that the company inclisiran harnesses natural mechanisms of the body for RNA silencing and further decreases LDL-C. This company analysis confirms that the administration of inclisiran twice-yearly results in potent and durable LDL-C reductions in Phase 3 trials.

Global Drug Development Head and Chief Medical Officer of Novartis, John Tsai stated that the outcomes presented reinforce the company’s belief that inclisiran is capable of being the first siRNA (small interfering RNA) agent that can help patients maintain their LDL-C to required levels.

Tsai further added that the unique twice a year dosing of inclisiran dosing easily fits in regular physician appointments and would help redefine how LDL-C is lowered and controlled in patients.

Source credit: https://www.novartis.com/news/media-releases/novartis-new-analysis-further-shows-durable-and-potent-ldl-c-reduction-inclisiran-investigational-first-class-sirna-cholesterol-lowering-treatment

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Xiaomi and Oppo team up with UNISOC to manufacture in-house 5G chipsets

Xiaomi and Oppo team up with UNISOC to manufacture in-house 5G chipsets

By Mateen Dalal

The two companies intend to introduce their custom-made sub-6GHz 5G chipsets by the end of 2021. UNISOC has managed to raise around USD 817.20 million for its new venture. Chinese electronics giants including Xiaomi Corp. and Guangdong Oppo Mob...

Twitter explored USD 4 billion takeover of audio-chat app Clubhouse

Twitter explored USD 4 billion takeover of audio-chat app Clubhouse

By Mateen Dalal

Twitter, an American microblogging service company, had touted plans of acquiring Clubhouse, an audio chat iPhone app and live drop-in audio networking platform. The deal was estimated to be valued at around USD 4 billion, as per reliable sources. T...

Beyond Meat sets up factory in China to expedite localized innovation

Beyond Meat sets up factory in China to expedite localized innovation

By Mateen Dalal

American plant-based meat substitute producer Beyond Meat has opened a new production facility in China. Apparently, this recent setup is the company’s first facility outside the U.S., making it the only multinational organization solely focusi...